Evidence map›Paper›PMID 40899793›Full record

ArticleAmerican journal of hematology2025

Triple A Plus (AAA

Ayalew Tefferi, Giuseppe G Loscocco, Lior Rokach, Tamar Tadmor, Priyansh Faldu, Guy Melamed, Hilel Alapi, Maymona Abdelmagid, Rania M Abdelaziz, Muhammad Yousuf and 12 more

Abstract readComparative StudyMulticenter StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Triple A Plus (AAAAmerican journal of hematology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ayalew TefferiDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-4605-3821
Giuseppe G LoscoccoCRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.ORCID 0000-0002-6241-1206
Lior RokachDepartment of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.ORCID 0000-0002-6956-3341
Tamar TadmorHematology Unit, Bnai Zion Medical Center, the Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel.ORCID 0000-0002-3435-8612
Priyansh FalduDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Guy MelamedKahn Sagol Maccabi Research and Innovation Center, Maccabi Healthcare Services, Tel-Aviv, Israel.
Hilel AlapiKahn Sagol Maccabi Research and Innovation Center, Maccabi Healthcare Services, Tel-Aviv, Israel.
Maymona AbdelmagidDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Rania M AbdelazizDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Muhammad YousufDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Merry NakhlehDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0009-0007-8646-5173
Animesh PardananiDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-9084-4148
Kebede H BegnaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-2730-8593
Mirnal M PatnaikDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6998-662X
Natasha SzuberDivision of Hematology, University of Montreal, Montreal, Quebec, Canada.ORCID 0000-0003-1499-6171
Alessandra CarobbioDepartment of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
Tiziano BarbuiFROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Kaaren K ReichardDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Rong HeDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6116-8163
Paola GuglielmelliCRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.ORCID 0000-0003-1809-284X
Naseema GangatDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-9104-6172
Alessandro M VannucchiCRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.ORCID 0000-0001-5755-0730

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survival prediction models in essential thrombocythemia (ET) include the International Prognostic Scoring System (IPSET) and the more recently introduced triple-A (AAA) prognostic score. The latter enlists age and absolute neutrophil (ANC) and lymphocyte (ALC) counts as risk variables. In the current study, a Mayo Clinic discovery cohort of 658 patients with ET was used to identify AAA-independent risk variables. Accordingly, multivariable analysis-derived HRs (95% CI) were 15.7 (8.4-29.5) for age > 70 years (8 points); 4.2 (2.3-7.5) for age 50 to 70 years (2 points); 1.8 (1.2-2.5) for ANC ≥ 8 × 10

Indexed as

Risk AssessmentThrombocythemia, EssentialAdolescentAdultAgedAged, 80 and overAge FactorsFemaleHumansHypertensionIsraelItalyLeukocyte CountMaleMiddle AgedMonocytesleukemialife‐expectancymyelofibrosismyeloproliferativepolycythemia

Identifiers

PMID40899793
PMCPMC12516648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.